Show simple item record

dc.contributor.authorCordero, Elisa
dc.contributor.authorBulnes-Ramos, Angel
dc.contributor.authorAguilar-Guisado, Manuela
dc.contributor.authorGonzález Escribano, Francisca
dc.contributor.authorOlivas, Israel
dc.contributor.authorTorre-Cisneros, Julian
dc.contributor.authorGavaldá, Joan
dc.contributor.authorAydillo, Teresa
dc.contributor.authorMoreno, Asunción
dc.contributor.authorMontejo, Miguel
dc.contributor.authorFariñas, María Carmen
dc.contributor.authorCarratalá, Jordi
dc.contributor.authorMuñoz, Patricia
dc.contributor.authorBlanes, Marino
dc.contributor.authorFortún, Jesús
dc.contributor.authorSuárez-Benjumea, Alejandro
dc.contributor.authorLópez-Medrano, Francisco
dc.contributor.authorRoca, Cristina
dc.contributor.authorLara, Rosario
dc.contributor.authorPerez-Romero, Pilar
dc.identifier.citationFront Immunol. 2020 Oct 6;11:1917.es_ES
dc.description.abstractOur goal was to study whether influenza vaccination induced antibody mediated rejection in a large cohort of solid organ transplant recipients (SOTR). Serum anti-Human Leukocyte Antigen (HLA) antibodies were determined using class I and class II antibody-coated latex beads (FlowPRATM Screening Test) by flow cytometry. Anti-HLA antibody specificity was determined using the single-antigen bead flow cytometry (SAFC) assay and assignation of donor specific antibodies (DSA) was performed by virtual-crossmatch. We studied a cohort of 490 SOTR that received an influenza vaccination from 2009 to 2013: 110 (22.4%) received the pandemic adjuvanted vaccine, 59 (12%) within the first 6 months post-transplantation, 185 (37.7%) more than 6 months after transplantation and 136 (27.7%) received two vaccination doses. Overall, no differences of anti-HLA antibodies were found after immunization in patients that received the adjuvanted vaccine, within the first 6 months post-transplantation, or based on the type of organ transplanted. However, the second immunization dose increased the percentage of patients positive for anti-HLA class I significantly compared with patients with one dose (14.6% vs. 3.8%; P = 0.003). Patients with pre-existing antibodies before vaccination (15.7% for anti-HLA class I and 15.9% for class II) did not increase reactivity after immunization. A group of 75 (14.4%) patients developed de novo anti-HLA antibodies, however, only 5 (1.02%) of them were DSA, and none experienced allograft rejection. Only two (0.4%) patients were diagnosed with graft rejection with favorable outcomes and neither of them developed DSA. Our results suggest that influenza vaccination is not associated with graft rejection in this cohort of SOTR.es_ES
dc.description.sponsorshipThis study was funded by the (Grant Number: PI-0119-2012), Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (Grant Numbers: GR09/0041, PI14-00165, and MPY110/18) and co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015/0001).es_ES
dc.publisherFrontiers Media es_ES
dc.subjectDonor specific antibodieses_ES
dc.subjectAnti-human leukocyte antigenes_ES
dc.subjectOrgan rejectiones_ES
dc.titleEffect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipientses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)
dc.contributor.funderRed Española de Investigación en Patología Infecciosa
dc.identifier.journalFrontiers in immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/REIPI RD12/0015/0001es_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional